B-type natriuretic peptide: A treatment not a diagnostic marker

Heart

Volumn 94, Issue 5, 2008, Pages 542-544

  Yip, Gabriel W ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; ENALAPRIL; GLYCERYL TRINITRATE; METOPROLOL; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR B; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; PLACEBO; URODILATIN;

ACUTE HEART INFARCTION; CLINICAL TRIAL; DISEASE MARKER; DRUG FATALITY; DRUG SAFETY; ECHOCARDIOGRAPHY; EDITORIAL; HEART FAILURE; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC PRECONDITIONING; KIDNEY DYSFUNCTION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

FEMALE; HUMANS; HYPOTENSION; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 42549160969     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2007.118380     Document Type: Editorial

References (30)

1. de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
2. Chen HH, Burnett JR. Clinical application of the natriuretic peptides in heart failure. Eur Heart J 2006;8(Suppl. E):E18-25.
3. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-8.
4. Boerrigter G, Burnett JC. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004;13:643-52.
5. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44:1328-33.
6. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168-74.
7. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
8. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007;49:1733-9.
9. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
10. Morrow DA, de Lemos JA, Blazing MA, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA 2005;294:2866-71.
11. Kragelund C, Gronning B, Kober L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-75.
12. Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA 2007;297:169-76.
13. Feringa HH, Schouten O, Dunkelgrun M, et al. Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery. Heart 2007;93:226-31.
14. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91.
15. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91. [Erratum in: Circulation 2005;111:2274]
16. Hillock RJ, Frampton CM, Yandle TG, et al. B-type natriuretic peptide infusions in acute myocardial infarction. Heart 2008;94:617-22.
17. Patel JB, Valencik ML, Pritchett AM, et al. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2005;289:H777-84.
18. Kapoun AM, Liang F, O'Young G, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004;94:453-61.
19. D'Souza SP, Yellon DM, Martin C, et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003;284:H1592-600.
20. Hayashi M, Tsutamoto T, Wada A, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001;37:1820-6.
21. Kasama S, Toyama T, Hatori T, et al. Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007;49:667-74.
22. Chen HH, Schirger JA, Wright RS, et al. Pilot study assessing dose and tolerability of BNP (nesiritide) infusion post anterior myocardial infarction to prevent adverse left ventricular remodeling and heart failure. J Card Fail 2004;10(Suppl 4):abstr 236.
23. Gilman G, Nelson TA, Hansen WH, et al. Diastolic function: a sonographer's approach to the essential echocardiographic measurements of left ventricular diastolic function. J Am Soc Echocardiogr 2007;20:199-209.
24. Jugdutt BI, Warnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988;78:906-19.
25. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327:678-84.
26. Chen ZM, Pan HC, Chen YP, et al. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of Clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607-21.
27. Chen HH, Lainchbury JG, Harty GJ, et al. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. Circulation 2002;105:999-1003.
28. Chen HH, Redfield MM, Nordstrom LJ. Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. J Card Fail 2004;10:115-9.
29. Cataliotti A, Schirger JA, Martin FL, et al. Oral human brain natriuretic peptide activates cyclic guanosine 3′5′- monophosphate and decreases mean arterial pressure. Circulation 2005;112:836-40.
30. Asakura M, Jiyoong K, Minamino T, et al. Rationale and design of a large-scale trial using atrial natriuretic peptide (ANP) as an adjunct to percutaneous coronary intervention for ST-segment elevation acute myocardial infarction: Japan-Working groups of acute myocardial infarction for the reduction of necrotic damage by ANP (J-WIND-ANP). Circ J 2004;68:95-100.